- ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference
- ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
- ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
- ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.
- ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event
- ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
- ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting
- ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting
More ▼
Key statistics
On Saturday, ADC Therapeutics SA (ADCT:NYQ) closed at 26.59, 5.92% above its 52-week low of 25.11, set on Oct 21, 2020.
52-week range
Markit short selling activity
Open | 28.73 |
---|---|
High | 28.92 |
Low | 26.11 |
Bid | 26.01 |
Offer | 27.97 |
Previous close | 28.48 |
Average volume | 188.70k |
---|---|
Shares outstanding | 76.72m |
Free float | 39.85m |
P/E (TTM) | -- |
Market cap | 2.04bn USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Feb 27 2021 00:00 GMT.
More ▼